Ex vivo activity of XR5000 against solid tumors

Anti-Cancer Drugs

Volumn 11, Issue 6, 2000, Pages 471-478

  Neale, Michael H ^a   Charlton, Peter A ^b   Cree, Ian A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

ATP; Chemosensitivity; Chemotherapy; Luminescence; Topoisomerase; XR5000

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; PACLITAXEL; TOPOTECAN; TREOSULFAN; UNCLASSIFIED DRUG; VINBLASTINE; XR 5000;

ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IC 50; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; SOLID TUMOR;

ACRIDINES; ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMILUMINESCENT MEASUREMENTS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; OVARIAN NEOPLASMS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033863154     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200007000-00008     Document Type: Article

References (47)

1. DNA topoisomerases
2. Clinical applications of anticancer drugs targeted to topoisomerase II
3. Current perspectives on camptothecins in cancer treatment
4. Cell death induced by topoisomerase-targeted drugs: More questions than answers
5. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities
6. The significance of the sequence of administration of topotecan and etoposide
7. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line
8. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer
9. Phase I and pharmacological study of sequential intravenous topo-tecan and oral etoposide
10. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action
11. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II
12. From amsacrine to DACA (N-[2-(dim ethylamino)ethyl] acridine-4-carboxamide): Selectivity for topoisomerases I and II among acridine derivatives
13. Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial
14. Phase I and pharmacokinetic study of DACA (XR5000) a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee
15. ATP based tumour chemosensitivity testing: Assisting new agent development
16. Bioluminescence of cellular ATP: A new method for evaluating cytotoxic agents in vitro
17. Estimation of biomass in growing cell lines by adenosine triphosphate assay
18. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing
19. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: Clinical correlation for cisplatin resistance of ovarian carcinoma
20. Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity
21. Chemotherapy directed by the ATP tumour chemosensitivity assay improves response rates and survival for patients with recurrent ovarian cancer
22. A randomised trial of chemotherapy directed by a tumour chemosensitivity assay versus physician's choice in patients with recurrent platinum-resistant ovarian adenocarcinoma
23. In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer
24. Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by microplate ATP bioluminescence assay
25. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: Laboratory study and clinical pilot trial
26. Expression of the p53 tumour suppressor gene product is a determinant of chemosensitivity
27. The influence of storage on cytotoxic drug activity in an ATP-based chemosensitivity assay
28. Quantitative estimation of potentiation and antagonism by dose ratios corrected for slopes of dose-response curves deviating from one
29. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma
30. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etopo-side in vitro
31. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process
32. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide
33. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines
34. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: A National Cancer Institute of Canada clinical trials group study
35. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells
36. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines
37. The Gynecologic Oncology Group experience in ovarian cancer
38. The potential of N-[2-(dimethylamino)ethy-1]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro
39. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells
40. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair
41. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts
42. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside
43. Selective cell kill of the combination of gemcitabine and cisplatin in multi-layered postconfluent tumor cell cultures
44. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines
45. DNA alkylation and interstrand cross-linking by treosulfan
46. The ex vivo chemosensitivity profile of choroidal melanoma
47. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo